US FDA approves MannKind's inhaled insulin for children
29/05/2026 17:35
US FDA approves MannKind's inhaled insulin for children May 29 (Reuters) - The U.S. Food and Drug Administration has approved expanded use of MannKind's MNKD.O inhaled rapid-acting insulin in children with diabetes, offering patients under 18 years of age a needle-free treatment option, the company said on Friday.
(Reporting by Siddhi Mahatole, Sahil Pandey and Sriparna Roy in Bengaluru; Editing by Diti Pujara)
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children